The stunning success of CAR T therapy over the past couple of years has spawned a new industry and a proliferation of CAR, TCR and TIL constructs. Engineering efforts are aimed at improving the design, targeting, developability, manufacturing, and scalability of new formats to solve issues that remain, including improving the safety of immunotherapy, affordability and targeting of solid tumors. The tumor microenvironment and the microbiome are being tapped to predict the efficacy of immunotherapy and optimize results.

Preliminary Agenda

QUEST FOR ALLOGENEIC CAR T CELLS

KEYNOTE PRESENTATION: Gene Edited Off-the-Shelf Immunotherapies

David Sourdive, PhD, Co-Founder, Executive Vice President, Corporate Development, Cellectis

Allogeneic CAR Therapies: Which Route to the Future?

Karl Peggs, MB, BCh, MA, MRCP, FRCPath, Professor, Transplant Science & Cancer Immunotherapy, University College London

CRISPR Edited Allogeneic T Cell Therapy

Waseem Qasim, PhD, NIHR Professor in Cell & Gene Therapy, Consultant in Paediatric Immunology/BMT, Institute of Child Health & Great Ormond Street Hospital

TARGETING SOLID TUMOURS

Developing Next-Generation Autologous and Allogeneic CAR T Cells without Gene Editing

Peggy Sotiropoulou, PhD, Director Research & Development, Celyad

CARs, TRUCKs and Beyond: Novel Strategies to Target Solid Cancer

Univ.-Prof. Dr. Hinrich Abken, MD, PhD, RCI, Regensburger Centrum für Interventionelle Immunologie, Lehrstuhl für Gen-Immuntherapie, Universitätsklinikum Regensburg

Clinical Strategies for Overcoming Challenges of Engineered T Cells in Solid Tumours

Fiona Thistlethwaite, MB, BChir, PhD, MRCP, Medical Oncology Consultant Experimental Cancer Medicine Team (ECMT); Honorary Senior Lecturer, Division of Cancer Sciences, Faculty of Biology Medicine & Health, The University of Manchester; iMATCH Director, The Christie NHS Foundation Trust

Polyfunctional Single Cell Analysis as a Key to Discovery and Predicting Patient Outcome

Peter Djali, European Director, Sales, IsoPlexis


Specificity Screening of Cell Therapies against Extensive Libraries of Plasma Membrane and Secreted Protein Targets

Diogo Rodrigues Ferreirinha, MSc, European Business Development Manager, Retrogenix Limited

TEGs: A New Avenue in Cellular Immunotherapy

Haakan Norell, PhD, Director, Discovery, Gadeta B.V.

Non-Viral Genetic Engineering of Cytokine-Induced Killer (CIK) Cells with Chimeric Antigen Receptors (CARs) for the Targeting of Acute Myeloid Leukemia

Sarah Tettamanti, PhD, Centro Ricerca M.Tettamanti, Clinica Pediatrica Ospedale S.Gerardo, Università Milano-Bicocca

TCR THERAPIES AND THEIR DERIVATIVES

Using Insight into TCR Functioning for an Improvement of CARs

Prof. Dr. Wolfgang Schamel, Institute of Biology III (Molecular Immunology) and BIOSS Centre for Biological Signaling Studies, University of Freiburg; Centre of Chronic Immunodeficiency, University Medical Centre Freiburg

Development of a Next Generation Immune Checkpoint Modulator towards the Clinic: A Humanized BTN3A Antibody (ICT01) Activating gamma9delta2 T Cells

Prof. Dr. René Hoet, PhD, CSO, Imcheck Therapeutics

Putting TCRs into Alpha Beta T Cells

Helen Tayton Martin, PhD, MBA, CBO, Adaptimmune

TILs AND GAMMA DELTA THERAPY

Preclinical Data and Clinical Plan for Developing Tumour Infiltrating Lymphocytes (TIL) for Solid Tumor Indications

Robert Hawkins, MB BS, MRCP, PhD, FRCP, Cancer Research UK Professor, Medical Oncology, University of Manchester; Honorary Consultant, Medical Oncology, Christie Hospital; Chief Executive Officer and Director, Immetacyte Ltd.

Gamma Delta CAR-T Cells Engineered for Avoidance of Toxicity and Dysfunction

John Anderson, PhD, GOSHCC Professor of Experimental Paediatric Oncology, Honorary Consultant Oncologist, UCL Great Ormond Street Institute of Child Health

Innate T Cells for the Treatment of Disease

Derek G. Doherty, PhD, Associate Professor, Trinity College Dublin; Head, Discipline of Immunology, Trinity Translational Medicine Institute, St. James's Hospital

NKTR-255, A Memory T-Cell Cytokine (IL-5) that Causes CAR T Expansion

Loui Madakamutil, PhD, Senior Vice President, Head of Biology and Preclinical Development, Nektar Therapeutics

PANEL DISCUSSION: CARs vs TCRs for Solid Tumours

Moderator: John Maher, FRCPath, PhD, Consultant & Senior Lecturer, Immunology, Cancer Studies, King’s College London



* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Japanese
Traditional Chinese
Simplified Chinese
Korean